Dr Andrew Conn is a consultant medical oncologist specialising in the non-surgical management of patients with bowel cancer, lung cancer and mesothelioma. This includes the use of chemotherapy as well as the latest targeted treatments.
Dr Conn trained in Medical Oncology at Nottingham University Hospitals NHS Trust and during this time undertook three years of laboratory based research as a Cancer Research UK Clinical Fellow. For his research into the development of a vaccine to treat colorectal cancer Dr Conn was awarded a Doctor of Philosophy degree by the University of Nottingham. In 2007 Dr Conn was appointed to the post of Consultant Medical Oncologist at Bradford Teaching Hospitals NHS Foundation Trust and Airedale NHS Foundation Trust.
Dr Conn takes pride in offering each patient with bowel cancer, lung cancer or mesothelioma a personalised treatment plan that guarantees access to the most effective treatments. In addition to chemotherapy this also includes the use of targeted therapies such as Avastin (bevacizumab), Erbitux (cetuximab) and Zaltrap (aflibercept) in bowel cancer and Xalkori (crizotinib), Iressa (gefitinib) and Tarceva (erlotinib) in lung cancer. This commitment to an individualised approach to patient care ensures the best possible outcomes for his patients.